Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 1/2 1

Status

Recruiting 3Completed 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Other solid neoplasm 4

Conditions

Mesothelioma 21Mesothelioma, Malignant 18Advanced Solid Tumor 17Carcinoma, Non-Small-Cell Lung 15Solid Tumor 14Advanced Solid Tumors 13Melanoma 12Esophageal Neoplasms 10Carcinoma, Renal Cell 10Stomach Neoplasms 9Squamous Cell Carcinoma of Head and Neck 9Uterine Cervical Neoplasms 8Solid Tumors 8Ovarian Neoplasms 8Solid Tumor, Adult 7Neoplasm Metastasis 7Colorectal Neoplasms 7Triple Negative Breast Neoplasms 6Small Cell Lung Carcinoma 6Breast Neoplasms 6Pancreatic Neoplasms 5Lung Neoplasms 5Endometrial Neoplasms 5Cholangiocarcinoma 5Neoplasms 4Locally Advanced or Metastatic Solid Tumors 4Head and Neck Neoplasms 4Advanced or Metastatic Solid Tumors 4Urinary Bladder Neoplasms 3Solid Tumor Malignancies 3

Interventions

pembrolizumab 4envafolimab 3Nivolumab 3Injections 2trifluridine tipiracil drug combination 1tebentafusp 1surufatinib 1sintilimab 1linifanib 1fludarabine 1cobimetinib 1TAK-981 1Ipilimumab 1Drug Therapy 1Doxorubicin 1Cyclophosphamide 1Combined Modality Therapy 1Bortezomib 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Advanced or Metastatic Solid Tumors × pembrolizumab × Other solid neoplasm × Clear all
NCT06234397 2026-03-11

Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors

Hanmi Pharmaceutical Company Limited

Phase 1 Recruiting
245 enrolled
Other solid neoplasm

Advanced or Metastatic Solid Tumors

NCT06724016 2025-12-17

Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tumors

Hanmi Pharmaceutical Company Limited

Phase 1 Recruiting
292 enrolled
Other solid neoplasm

Advanced or Metastatic Solid Tumors

NCT04381650 2025-12-10

A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors

Takeda

Phase 1/2 Completed
161 enrolled 44 charts
Other solid neoplasm

Advanced or Metastatic Solid Tumors

NCT05785754 2025-06-26

DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors

DynamiCure Biotechnology

Phase 1 Recruiting
320 enrolled
Other solid neoplasm

Advanced or Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡